By analyzing scRNA-seq data from 66 mild and 48 moderate COVID-19 patients, we examined the CD8+ T cell activation program in these patients and asked how it changes during the mild-to-moderate disease severity transition. This evidence concerns the gene CD8A and COVID-19.